UBS Group’s Viveon Health Acquisition Corp. Rights, each exchangeable into one-twentieth of a share of Common Stock VHAQ.RT Stock Holding History

UBS Group’s Portfolio VHAQ.RT Stock Details VHAQ.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-120	Closed	-$6	–	10033
2023 Q1	$6	Buy	+120	New	+$11	﹤0.01%	9485
2022 Q4	–	Sell	-26,783	Closed	-$3K	–	11378
2022 Q3	$3K	Hold	26,783	–	–	﹤0.01%	9630
2022 Q2	$2K	Hold	26,783	–	–	﹤0.01%	9674
2022 Q1	$3K	Buy	26,783 +2,815	+12%	+$449	﹤0.01%	9523
2021 Q4	$4K	Hold	23,968	–	–	﹤0.01%	9573
2021 Q3	$5K	Buy	23,968 +19,799	+475%	+$4.37K	﹤0.01%	8576
2021 Q2	$1K	Buy	+4,169	New	+$859	﹤0.01%	9222

Other funds holding VHAQ.RT

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OCAM

Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

ASM

ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

BCM

Bluefin Capital Management New York $156M AUM 18.47% 1-Year Est. Return

UBS Group's VHAQ.RT Position: Q2 2023 in Review

UBS Group sold out of Viveon Health Acquisition Corp. Rights, each exchangeable into one-twentieth of a share of Common Stock (VHAQ.RT) in Q2 2023, closing a stake of 120 shares — an estimated $6 sold.

UBS Group first reported a position in VHAQ.RT in Q2 2021 and held it in 7 quarters. The position peaked at $5K in Q3 2021. 28 funds tracked by Wall St. Rank hold VHAQ.RT as of Q2 2023.

UBS Group reported no remaining Viveon Health Acquisition Corp. Rights, each exchangeable into one-twentieth of a share of Common Stock position as of Q2 2023 after selling out during the quarter.
UBS Group sold 120 Viveon Health Acquisition Corp. Rights, each exchangeable into one-twentieth of a share of Common Stock shares in Q2 2023, an estimated $6.
UBS Group first reported a position in Viveon Health Acquisition Corp. Rights, each exchangeable into one-twentieth of a share of Common Stock in Q2 2021 and held it in 7 quarters.
UBS Group's Viveon Health Acquisition Corp. Rights, each exchangeable into one-twentieth of a share of Common Stock position peaked at $5K in Q3 2021.
28 funds tracked by Wall St. Rank held Viveon Health Acquisition Corp. Rights, each exchangeable into one-twentieth of a share of Common Stock as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.